default author photo

Christo H van Niekerk

affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

217

TOTAL CITATIONS

6

Scholarly Papers (1)

1.

A Partially-Randomised Phase 3 Trial of Pretomanid, Moxifloxacin and Pyrazinamide in Combination for the Treatment of Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis

Number of pages: 151 Posted: 14 Feb 2020
University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit, Kenyatta National Hospital, National Centre for Pulmonary Research, Pusat Perubatan Universiti Kebangsaan, University College London, Global Alliance for TB Drug Development, Aurum Institute for Health Research, Makati Medical Centre, Johns Hopkins University - School of Medicine, St. Andrews University, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), University of Cape Town Lung Institute, Global Alliance for TB Drug Development, Stellenbosch University, Global Alliance for TB Drug Development, University College London - MRC Clinical Trials Unit, University College London, Universiti Teknologi MARA (UiTM), Wentworth Hospital, Global Alliance for TB Drug Development, Madibeng Centre for Research, Setshaba Research Centre, University College London, Global Alliance for TB Drug Development, Ifakara Health Institute, THINK TB & HIV Investigative Network, Kenya Medical Research Institute (KEMRI) - Centre for Respiratory Diseases Research, University College London - MRC Clinical Trials Unit, National Institute for Medical Research (NIMR), Aurum Institute for Health Research, Aurum Institute for Health Research, University of Nebraska Medical Center, University of Nebraska Medical Center, affiliation not provided to SSRN, Klerksdorp-Tshepong Hospital Complex - Department of Medicine, Global Alliance for TB Drug Development and St. Andrews University
Downloads 217 (353,017)
Citation 6

Abstract:

Loading...

Tuberculosis; TB; drug-sensitive tuberculosis; DS-TB; MDR-TB; multidrug-resistant TB; regimen development; pretomanid, moxifloxacin, pyrazinamide; ethambutol; HRZE, phase 3 clinical trial; PaMZ